Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib in MF/SS and T-LGLL (GEMSTONE)
NCT07682792Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in mycosis fungoides (MF), Sézary syndrome (SS), T-cell large granular lymphocytic leukemia, sponsored by Washington University School of Medicine. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)T-cell large granular lymphocytic leukemia
Beyond the preview
Go deeper on NCT07682792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07682792.